Virax Biolabs Group Overview
Virax Biolabs Group (VRAX) has a P/E ratio of -0.16, below the sector sector average of 44.85.
Get informed when a big investor buys or sells
+ Follow-0.16
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Virax Biolabs Group posts a P/E ratio of -0.16. That is below the sector sector average of 44.85. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For its sector stocks, a P/E ratio near 44.85 is typical. Virax Biolabs Group's -0.16 is lower that level. That is roughly 100.4% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Virax Biolabs Group's P/E ratio of -0.16 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.
Context for VRAX's P/E ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 44.85), and (3) consistency with growth and profitability. This page covers the first two; Virax Biolabs Group's other metric pages and overview cover the third.
